Upsher-Smith Laboratories, a subsidiary of Bora Pharmaceuticals, has launched Brimonidine Tartrate Ophthalmic Solution 0.1% and Brimonidine Tartrate Ophthalmic Solution 0.15%. According to IQVIA, the U.S. market for these dosage strengths had sales of approximately $115 million for September 2025 through August 2026.
The 0.1% strength has a Therapeutic Equivalence Code of AB, while the 0.15% strength has a TE code of AT. The reference listed drug for both products is ALPHAGAN P.
Both strengths are available in 5 mL, 10 mL and 15 mL solution sizes, packaged in 10 mL, 10 mL and 15 mL bottles respectively. The 0.1% strength carries NDC numbers 0832-1435-05, 0832-1435-10 and 0832-1435-15, and the 0.15% strength carries NDC numbers 0832-1420-05, 0832-1420-10 and 0832-1420-15.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!